• Je něco špatně v tomto záznamu ?

COVID-19-associated pulmonary aspergillosis (CAPA): identification of Aspergillus species and determination of antifungal susceptibility profiles

A. Ozturk, T. Bozok, M. Erdogan, BM. Ibrahim, TS. Bozok

. 2023 ; 68 (6) : 951-959. [pub] 20230609

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23020584

Among the co-infectious agents in COVID-19 patients, Aspergillus species cause invasive pulmonary aspergillosis (IPA). IPA is difficult to diagnose and is associated with high morbidity and mortality. This study is aimed at identifying Aspergillus spp. from sputum and tracheal aspirate (TA) samples of COVID-19 patients and at determining their antifungal susceptibility profiles. A total of 50 patients with COVID-19 hospitalized in their intensive care units (ICU) were included in the study. Identification of Aspergillus isolates was performed by phenotypic and molecular methods. ECMM/ISHAM consensus criteria were used for IPA case definitions. The antifungal susceptibility profiles of isolates were determined by the microdilution method. Aspergillus spp. was detected in 35 (70%) of the clinical samples. Among the Aspergillus spp., 20 (57.1%) A. fumigatus, six (17.1%) A. flavus, four (11.4%) A. niger, three (8.6%) A. terreus, and two (5.7%) A. welwitschiae were identified. In general, Aspergillus isolates were susceptible to the tested antifungal agents. In the study, nine patients were diagnosed with possible IPA, 11 patients were diagnosed with probable IPA, and 15 patients were diagnosed with Aspergillus colonization according to the used algorithms. Serum galactomannan antigen positivity was found in 11 of the patients diagnosed with IPA. Our results provide data on the incidence of IPA, identification of Aspergillus spp., and its susceptibility profiles in critically ill COVID-19 patients. Prospective studies are needed for a faster diagnosis or antifungal prophylaxis to manage the poor prognosis of IPA and reduce the risk of mortality.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23020584
003      
CZ-PrNML
005      
20231215110120.0
007      
ta
008      
231215s2023 xr f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12223-023-01069-5 $2 doi
035    __
$a (PubMed)37294497
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ozturk, Ali $u Department of Medical Microbiology, Faculty of Medicine, Nigde Omer Halisdemir University, Nigde, Turkey. ali.81ozturk@gmail.com $1 https://orcid.org/0000000324281831
245    10
$a COVID-19-associated pulmonary aspergillosis (CAPA): identification of Aspergillus species and determination of antifungal susceptibility profiles / $c A. Ozturk, T. Bozok, M. Erdogan, BM. Ibrahim, TS. Bozok
520    9_
$a Among the co-infectious agents in COVID-19 patients, Aspergillus species cause invasive pulmonary aspergillosis (IPA). IPA is difficult to diagnose and is associated with high morbidity and mortality. This study is aimed at identifying Aspergillus spp. from sputum and tracheal aspirate (TA) samples of COVID-19 patients and at determining their antifungal susceptibility profiles. A total of 50 patients with COVID-19 hospitalized in their intensive care units (ICU) were included in the study. Identification of Aspergillus isolates was performed by phenotypic and molecular methods. ECMM/ISHAM consensus criteria were used for IPA case definitions. The antifungal susceptibility profiles of isolates were determined by the microdilution method. Aspergillus spp. was detected in 35 (70%) of the clinical samples. Among the Aspergillus spp., 20 (57.1%) A. fumigatus, six (17.1%) A. flavus, four (11.4%) A. niger, three (8.6%) A. terreus, and two (5.7%) A. welwitschiae were identified. In general, Aspergillus isolates were susceptible to the tested antifungal agents. In the study, nine patients were diagnosed with possible IPA, 11 patients were diagnosed with probable IPA, and 15 patients were diagnosed with Aspergillus colonization according to the used algorithms. Serum galactomannan antigen positivity was found in 11 of the patients diagnosed with IPA. Our results provide data on the incidence of IPA, identification of Aspergillus spp., and its susceptibility profiles in critically ill COVID-19 patients. Prospective studies are needed for a faster diagnosis or antifungal prophylaxis to manage the poor prognosis of IPA and reduce the risk of mortality.
650    _2
$a lidé $7 D006801
650    _2
$a antifungální látky $x farmakologie $x terapeutické užití $7 D000935
650    12
$a COVID-19 $x komplikace $7 D000086382
650    _2
$a Aspergillus $7 D001230
650    12
$a plicní aspergilóza $x diagnóza $x farmakoterapie $x komplikace $7 D055732
650    12
$a invazivní plicní aspergilóza $x diagnóza $x farmakoterapie $x komplikace $7 D055744
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bozok, Taylan $u Department of Medical Microbiology, Faculty of Medicine, Mersin University, Mersin, Turkey
700    1_
$a Erdogan, Merve $u Department of Medical Microbiology, Faculty of Medicine, Sanko University, Gaziantep, Turkey
700    1_
$a Ibrahim, Bashar Ms $u Department of Pharmaceutical Microbiology, Suleyman Demirel University, Isparta, Turkey $1 https://orcid.org/0000000330860995
700    1_
$a Bozok, Tugce Simsek $u Department of Infectious Diseases and Clinical Microbiology, Mersin University Hospital, Mersin, Turkey
773    0_
$w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 68, č. 6 (2023), s. 951-959
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37294497 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231215 $b ABA008
991    __
$a 20231215110113 $b ABA008
999    __
$a ok $b bmc $g 2021886 $s 1207023
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 68 $c 6 $d 951-959 $e 20230609 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
LZP    __
$a Pubmed-20231215

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace